
News|Podcasts|March 20, 2026
ACT Brief: Wearable Data Integration Challenges, Human Performance Science, and Rare Disease Regulatory Flexibility
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we explore the data overload and alert fatigue challenges in integrating wearable data into clinical workflows, how cognitive and behavioral science can transform site readiness and training, and FDA's evolving guidance on rare disease trial design and evidence standards.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In part three of his video
interview , Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, addressed challenges in integrating wearable data into clinical workflows. High-velocity continuous data from remote monitors creates information overload for providers managing large patient cohorts, and frequent false alarms lead clinicians to ignore potentially dangerous alerts. - In a new ACT Academy
session developed by Brian S. McGowan, PhD, Chief Learning Officer at ArcheMedX, the focus shifted to cognitive, learning, and behavioral science as drivers of clinical performance. Using spaced repetition and behavioral nudges, this approach builds true readiness and translates knowledge into consistent action under pressure, moving beyond compliance-driven training checkboxes. - In a new
interview from Pharmaceutical Executive, Laksheeta Johari, analyst for Lifescience Dynamics, discussed how FDA's Rare Disease Evidence Principles allow sponsors greater flexibility in trial design and control arms while maintaining safety as paramount. Recent CRLs suggest FDA application may diverge from stated guidance, creating uncertainty and signaling a need for better alignment across regulatory touchpoints.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Trending on Applied Clinical Trials Online
1
NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market
2
Real-Time Clinical Trials: What the FDA's Push Toward Continuous Oversight Means for Sponsors
3
ACT Brief: Real-Time Trial Infrastructure Gaps, Built-In Data Security, and AI-Enabled CDMO Value
4
ACT Brief: DIA Leadership and Infrastructure Priorities, Real-Time Data Review Readiness, and CLL Treatment Expansion
5



